Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

575
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

496
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
496
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

552
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
552
Socioemotional Experience and Gender Development01:30

Socioemotional Experience and Gender Development

332
Social-emotional experiences and cultural influences play significant roles in shaping gender development. During middle childhood, from ages 6 to 11, peer groups become dominant in reinforcing gender norms. Children in this age group often align with same-gender peer groups, which actively encourage behaviors that conform to traditional gender roles. For instance, boys may be discouraged from engaging in activities perceived as feminine, reinforcing culturally dictated norms about masculinity...
332
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

459
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
459
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

611
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex Differences in Heart Transplantation Outcomes: A 5-Year Review of the 2018 U.S. Allocation Policy.

JACC. Advances·2026
Same author

Response to letter regarding maternal and fetal outcomes across hypertensive pregnancy subtypes.

International journal of cardiology. Cardiovascular risk and prevention·2025
Same author

Coronary Computed Tomography Angiography to Guide Percutaneous Coronary Intervention: Expert Opinion from a SCAI/SCCT Roundtable.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Sex Differences in Utilization of Donation After Circulatory Death Donors for Heart Transplantation and Associated Outcomes.

Circulation. Heart failure·2025
Same author

From Normal to Zero Flow in 30 Seconds on HeartMate 3 LVAD: What Happened?

JACC. Case reports·2025
Same author

When Do Microbubbles Become Macrobubbles in Laser PCI?

JACC. Case reports·2025

Related Experiment Video

Updated: Feb 5, 2026

Skeletal Muscle Gender Dimorphism from Proteomics
09:29

Skeletal Muscle Gender Dimorphism from Proteomics

Published on: December 14, 2011

13.0K

Gender Differences in Ischemic Cardiomyopathy.

Laura Divoky1, Anbukarasi Maran1, Bhavadharini Ramu2

  • 1Division of Cardiology, Department of Medicine, Medical University of South Carolina (MUSC), Strom Thurmond Gazes Building, 30 Courtenay Drive, BM 212, MSC 592, Charleston, SC, 29425, USA.

Current Atherosclerosis Reports
|September 5, 2018
PubMed
Summary
This summary is machine-generated.

Cardiovascular disease (CVD) disproportionately affects women, leading to higher mortality from ischemic heart disease. This review highlights gender-specific challenges in diagnosing and treating ischemic cardiomyopathy in women, aiming to improve outcomes.

Keywords:
Coronary artery diseaseGenderGender disparitiesHeart failureIschemic cardiomyopathyWomen

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.5K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Related Experiment Videos

Last Updated: Feb 5, 2026

Skeletal Muscle Gender Dimorphism from Proteomics
09:29

Skeletal Muscle Gender Dimorphism from Proteomics

Published on: December 14, 2011

13.0K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.5K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Area of Science:

  • Cardiology
  • Women's Health
  • Medical Research

Background:

  • Cardiovascular disease (CVD) is the leading global cause of death in women.
  • Ischemic heart disease accounts for the majority of CVD deaths in women.
  • Women with ischemic cardiomyopathy face significant morbidity and mortality.

Purpose of the Study:

  • To review gender-specific differences in the burden, clinical presentation, and outcomes of ischemic cardiomyopathy in women.
  • To identify challenges in the diagnosis and management of CVD in women.
  • To highlight areas for future research to improve outcomes for women.

Main Methods:

  • Literature review focusing on gender differences in ischemic cardiomyopathy.
  • Analysis of current clinical practices and outcomes for women with CVD.
  • Identification of knowledge gaps and research needs.

Main Results:

  • Women experience poorer outcomes in ischemic cardiomyopathy due to various factors.
  • Delays in presentation, diagnosis, and treatment contribute to adverse outcomes.
  • Under-representation of women in clinical trials limits evidence-based guidelines.

Conclusions:

  • Addressing gender-specific nuances is crucial for improving women's cardiovascular health.
  • Further research is needed to understand and mitigate sex-based disparities in ischemic cardiomyopathy.
  • Tailored diagnostic and management strategies are essential for better patient outcomes.